Antitumour effectiveness of hyperthermia is potentiated by local application of electric pulses to LPB tumours in mice

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2343-2348

  Karner, Katarina Barbara ^a   Lesnicar, Hotimir ^a   Cemazar, Maja ^a   Sersa, Gregor ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Animal tumour model; Electroporation; Hyperthermia; Tumour perfusion

Indexed keywords

3 METHYLCHOLANTHRENE; DISULFINE BLUE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTROPORATION; ELECTROSTIMULATION THERAPY; FEMALE; FIBROSARCOMA; HISTOLOGY; HYPERTHERMIA; HYPERTHERMIC THERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TISSUE PERFUSION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; COMBINED MODALITY THERAPY; ELECTROPORATION; FEMALE; FIBROSARCOMA; HYPERTHERMIA, INDUCED; MALE; MICE; MICE, INBRED C57BL; PERFUSION; RANDOM ALLOCATION; SARCOMA, EXPERIMENTAL;

EID: 4444372709     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Falk MH and Issels RD: Hyperthermia in oncology. Int J Hyperther 17: 1-18, 2001.
2. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R and Riess H: The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hemat 43: 33-56, 2002.
3. Takemoto M, Kuroda M, Urano M, Nishimura Y, Kawasaki S, Kato H, Okumura Y, Akaki S, Kanazawa S, Asaumi J, Joja I and Hiraki Y: The effects of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperther 19: 193-203, 2003.
4. Dewey WC: Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperther 10: 457-483, 1994.
5. Roti Roti JL, Kampinga HH, Malyapa RS, Wright WD and vanderWaal RP: Nuclear matrix as a target for hyperthermic killing of cancer cell. Cell Stress Chaperon 3: 245-255, 1998.
6. Stewart F and Begg A: Blood flow changes in transplanted mouse tumours and skin after mild hyperthermia. Br J Radiol 56: 477-482, 1983.
7. Song CW: Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 44: 4721-4730, 1984.
8. Song CW, Shakil A, Osborn JL and Iwata K: Tumour oxygenation is increased by hyperthermia at mild temperatures. Int J Hyperther 12: 367-373, 1996.
9. Brown SL, Hunt JW and Hill RP: Differential thermal sensitivity of tumour and normal tissue microvascular response during hyperthermia. Int J Hyperther 8: 501-514, 1992.
10. Horsman MR and Overgaard J: Can mild hyperthermia improve tumour oxygenation? Int J Hyperther 13: 141-147, 1997.
11. Horsman MR and Murata R: Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 54: 1518-1523, 2002.
12. Orlowski S and Mir LM: Cell electropermeabilisation: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta 1154: 51-63, 1993.
13. Mir LM: Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry 53: 1-10, 2000.
14. Jaroszeski MJ, Heller R and Gilbert R: Electrochemotherapy, Electrogenetherapy and Transdermal Drug Delivery. Electrically Mediated Delivery of Molecules to Cells. New Jersey, Humana Press. 2000.
15. Sersa G, Cemazar M and Rudolf Z: Electrochemotherapy: advantages and drawbacks in treatment of cancer patients. Cancer Therapy 1: 133-142, 2003.
16. Sersa G, Cemazar M, Parkins CS and Chaplin DJ: Tumour blood flow changes induced by application of electric pulses. Eur J Cancer 35: 672-677, 1999.
17. Sersa G, Cemazar M, Miklavcic D and Chaplin DJ: Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res 19: 4017-4022, 1999.
18. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, Coer A, Swartz HM and Cemazar M: Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer. 87: 1047-1054, 2002.
19. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin DJ, Double J, Embleton J, Newell D, Rymond R, Stables J, Stephens T and Wallace J: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 77: 1-10, 1998.
20. Spector SA, Tyndall M and Kelley E: Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. Am J Med 73: 36-39, 1982.
21. Gehl J and Geertsen PF: Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 10: 585-589, 2000.
22. Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM and Sersa G: Electroporation of human microvascular endothelial cells: evidence for anti-vascular mechanism of electrochemotherapy. Br J Cancer 84: 556-570, 2001.
23. Gehl J, Skovsgaard T and Mir LM: Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochim Biophys Acta 1569: 51-58, 2002.
24. Cemazar M, Parkins CS, Holder AL, Kranjc S, Chaplin DJ and Sersa G: Cytotoxicity of bioreductive drug tirapazamine is increased by application of electric pulses in SA-1 tumours in mice. Anticancer Res 21: 1151-1156, 2001.
25. Honess DJ, Hu DE and Bleehen NM: A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour. Int J Hyperther 7: 667-679, 1991.
26. Horsman MR, Sampson LE, Chaplin DJ and Overgaard J: The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperther 12: 779-789, 1996.
27. Eikesdal HP, Schem BC, Mella O and Dahl O: The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys 46: 645-652, 2000.
28. Murata R, Overgaard J and Horsman MR: Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperther 17: 508-519, 2001.